Genetic Evaluation Practices in Living Kidney Donor Candidates Authors: Yasar Caliskan, Ozgur Akin Oto, Tarek Alhamad, Halil Yazici, Arzu Velioglu, Abdulmecit Yildiz, Danilo Radunovic, Neetika Garg, Andreas Kousios, Zeynep Ural, Christina Mejia, Ondrej Viklicky, John Sayer, Arksarapuk Jittirat, Mingyao Becky Ma, Mohit Madken, Sultan Ozkurt, Reem Daloul, Hernando Trujillo, Karim Soliman, Giuseppe Castellano, Aydin Turkmen, Carlo Alfieri, Adil Manzoor, Brian Lee, Christie P. Thomas, Roslyn B. Mannon, Krista L. Lentine Published: 2026 ABSTRACT IntroductionAlthough genetic testing is increasingly used in evaluating living kidney donor (LKD) candidates and recipients, objective data on genetic testing practices are limited. This study aimed to describe current genetic testing practices in LKD evaluation using data from the international living donor genetic registry.MethodsA research electronic data capture (REDCap) registry was developed to collect cross-sectional, deidentified information on LKD candidates and genetic test results. Participating centers registered candidates meeting at least 1 of the following criteria: (i) underwent genetic testing; (ii) family history of genetic kidney disease; and/or (iii) were evaluated to donate to a biologically related recipient with kidney disease of unknown etiology. Data were collected between June 1, 2023 and November 10, 2025.ResultsAmong 1259 LKD evaluations from 24 centers (10 US, 14 international), genetic testing was performed in 295 (23.4%). US donor candidates were younger (median 39 vs. 48 years, P < 0.001). Testing strategies differed by region as follows: international centers predominantly used recipient-first testing (92.1%), whereas US centers more often performed direct LKD testing (61.5%; P < 0.001). These differences persisted after excluding apolipoprotein L-1 (APOL1) testing, with direct LKD candidate testing remaining more common in US (34.0% vs. 7.9%; P < 0.001). Among tested LKD candidates, 20.7% (61/295) were not approved for donation, with 7.8% (23/295) attributed to genetic findings. In multivariable analysis, younger donor age was independently associated with LKD nonacceptance (adjusted odds ratio [OR]: 0.89 per-year; 95% confidence interval [CI]: 0.83–0.95; P < 0.001).ConclusionGenetic testing practices vary substantially across regions, with US centers favoring direct LKD testing and international centers using recipient-first approaches. Younger donor candidate age was independently associated with nonacceptance. Living kidney donor (LKD) transplantation is the preferred treatment option for patients with kidney failure, offering superior outcomes and reduced wait times compared with deceased donor transplantation.1,2 However, living kidney donation comes with long term risks, including an increased risk of kidney failure, when compared with demographically matched nondonor controls.3, 4, 5, 6 Although the underlying reasons for this risk are not fully defined, several clinical factors have been associated with increased postdonation kidney failure, including older age, male sex, higher body mass index, hypertension, and African ethnicity.3,5,7, 8, 9, 10, 11, 12, 13, 14 This risk maybe influenced by genetic predisposition, since donors biologically related to their recipients have higher rates of kidney failure compared with unrelated donors.15 Identifying and mitigating these risks requires an understanding of how genetic factors influence kidney disease susceptibility, both for donors and their intended recipients.9 Genetic testing has recently gained traction as a valuable tool in the evaluation of LKD candidates, offering insights into possible heritable conditions that could impact donor eligibility or postdonation health outcomes.9,10,14 Despite its potential, the adoption of genetic testing in the evaluation of LKD candidates remains inconsistent across transplant centers, with significant variability in testing practices, reporting standards, and clinical applications. The lack of standardized guidelines poses challenges in ensuring equitable and evidence-based care for LKDs and their recipients. To address these challenges, we established the Living Donor Genetic Registry (LDGen), a multicenter consortium aimed at evaluating genetic testing practices in LKD transplants. This collaborative effort seeks to inform clinical decision-making and improve outcomes for LKDs and recipients. Herein we present the findings from LDGen and highlight its role in advancing the standardization of genetic testing practices in LKD transplants internationally. Methods Study Design and Participants The LDGen registry was established in January 2023 as a multinational collaborative effort. A total of 24 transplant centers from 10 countries participated, including the United States (n = 10), Turkey (n = 6), and 1 center each from China, Czech Republic, Cyprus, Italy, Montenegro, Pakistan, Spain, and United Kingdom. A cross-sectional, electronic REDCap registry was developed to collect comprehensive information on LKD candidates and their genetic test results. All participating centers were instructed to enter donor evaluations meeting the predefined inclusion criteria to minimize selection bias and enhance representativeness across sites. Participating transplant centers registered LKD candidates to LDGen if they met 1 or more of the following criteria: (i) underwent genetic testing; (ii) had a family history of genetic kidney disease; and/or (iii) were being evaluated to donate to a biologically related transplant candidate with chronic kidney disease of unknown etiology. Data were collected between June 1, 2023 and November 10, 2025. This targeted inclusion ensures a robust dataset for examining the role of genetic factors in living kidney donation and transplantation. Ethical Considerations The LDGen Registry operates under strict ethical oversight to ensure the protection of patient rights, privacy, and well-being. Data are collected in a fully deidentified manner, ensuring protection of participant privacy and adherence to ethical standards. The study protocol was reviewed and approved by Saint Louis University Institutional Review Board (IRB; Protocol# 32510) in agreement with the Declaration of Helsinki. To streamline oversight and coordination, Saint Louis University IRB served as the central IRB for the LDGen Registry. All participating transplant centers obtained approval from their respective IRBs or Ethics Committees before contributing data. After central and local IRB approval, transplant center staff were responsible for identifying eligible LKD candidates and entering relevant demographic, clinical, and genetic testing information into the secure REDCap platform. All data was deidentified and stored in a secure, centralized database. The clinical and research activities being reported are consistent with the Principles of the Declaration of Istanbul as outlined in the Declaration of Istanbul on Organ Trafficking and Transplant Tourism. Data Collection For the current analysis, data were extracted from the LDGen Registry for entries recorded between June 1, 2023 and November 10, 2025. During this period, participating transplant centers contributed information on LKD and intended recipients, including demographic characteristics, relevant family history, clinical context of evaluation, and results of genetic testing derived from accredited laboratories, while acknowledging that independent variant validation was not part of the registry design. The types of genetic tests performed were categorized as single gene or limited gene panel, comprehensive kidney disease gene panel, whole exome sequencing, APOL1 renal risk variant (RRV) testing, and cascade testing, with unspecified test types also noted. Indications for genetic testing and the selection of test type were determined by each institution and were influenced by the genetic tests available within the respective country and institution. The analysis also assessed the proportion of LKD and recipient candidates who received formal genetic counseling during the evaluation process. Positive genetic results in transplant recipient or donor candidates were initially identified by individual transplant centers using the 2015 American College of Medical Genetics and Genomics guidelines.16 Each center classified variants using standard American College of Medical Genetics and Genomics terminology including pathogenic, likely pathogenic, variants of uncertain significance (VUS), likely benign, or benign, and entered these data into the REDCap system.16 All reported variants subsequently underwent centralized re-evaluation by the LDGen team, with interpretation and classification performed in accordance with American College of Medical Genetics and Genomics guidelines.16,17 Variants considered positive and potentially relevant for clinical decision-making included all pathogenic and likely pathogenic variants that the transplant center determined to be relevant to the recipient candidate’s clinical phenotype as well as carriage of APOL1 2 renal risk variants (high-risk genotype). Clinical Outcomes The primary outcomes of interest for this study included the following approaches to genetic evaluation of LKD candidates: whether testing was initiated in the recipient candidate or the LKD candidate, types of genetic tests performed, and the impact of genetic testing results on LKD candidate eligibility. Outcomes were stratified by whether the LKD candidate evaluation occurred at a US or international transplant center. LKD candidate acceptance rates were evaluated, with particular attention to those not accepted because of genetic testing results, including findings of pathogenic or likely pathogenic variants and APOL1 RRVs. Statistical Analyses Descriptive statistics were performed using frequencies with percentages for categorical variables, whereas results for continuous variables are expressed as mean ± SD when normally distributed or median with interquartile ranges (IQR) when not normally distributed. Appropriate parametric and nonparametric tests were used accordingly. Comparisons of continuous variables between the groups were evaluated using t-test or the Mann-Whitney U test, where appropriate. Differences in the proportions of different groups were compared using the chi-squared or Fisher’s exact test. Logistic regression analysis was conducted to identify predictors of nonacceptance for donation. Predictor variables included recipient candidate age, recipient candidate sex, donor candidate age, donor candidate sex, donor candidate self-identified ethnicity, donor-recipient relationship, recipient's primary kidney disease, evaluation at a US versus international center, degree of donor-recipient relationship, genetic testing method, and genetic testing results. Univariable and multivariable logistic regression tests were used to explore associations. ORs, 95% CIs, and P-values were reported. Although the proportion of missing data was minimal, 93 cases with incomplete data entry (as shown in Figure 1) were excluded from the analysis. Therefore, analyses were conducted on complete cases without imputation. All analyses were 2-sided, and a P value < 0.05 was considered statistically significant. Statistical analyses were performed using SPSS for Windows (version 21.0, IBM Corp., Armonk, NY) and R (version 4.3.2, R Project for Statistical Computing, Vienna, Austria).Figure 1Summary of LDGen entries from June 2023 to November 2025. The flowchart illustrates the structure of the living kidney donor (LKD) genetic evaluation process and summarizes the types of genetic testing performed during candidate assessment. LDGen, Living Donor Genetic Registry; APOL1 RRV, apolipoprotein L-1 renal risk variant. Summary of LDGen entries from June 2023 to November 2025. The flowchart illustrates the structure of the living kidney donor (LKD) genetic evaluation process and summarizes the types of genetic testing performed during candidate assessment. LDGen, Living Donor Genetic Registry; APOL1 RRV, apolipoprotein L-1 renal risk variant. Results LDGen Registry Cohort Data were collected from 1259 LKD evaluations across 10 US (18.9%, 237/1259) and 14 international centers (81.2%, 1022/1259). The median age of the LKD candidates was 47 (IQR: 38–55) years, with women comprising 55.7% (702/1259) of the cohort. Most of the reported LKD candidates (80.5%, 1013/1259) were biologically related to their intended recipients. Figure 1 illustrates the structure of the LDGen registry cohort and summarizes the genetic testing approaches during candidate assessment. Table 1 summarizes the demographic and relational characteristics of the LKD candidates, stratified by geographic origin (US vs. international). Donor candidates from the US were significantly younger (median age 39 vs. 48 years, P < 0.001) and more likely to self-identify as non-European ethnicity, with higher proportions of African American and Native American LKD candidates compared with the international cohort (P < 0.001). Although sex distribution was similar across groups, the composition of related LKD and recipient candidate relationships differed. US related LKD candidates were more frequently children rather than parents of the recipient candidate (P < 0.001; Table 1).Table 1Living kidney donor candidate characteristicsDonor candidate characteristicAll (N = 1259)United States (n = 237)International (n = 1022)P-valueAge, median (IQR)47 (38–55)39 (31–49)48 (39–56)< 0.001Sex, female / male n (%)702 (56%)/557 (44%)135 (57%)/102 (43%)567 (55%)/455 (45%)0.73Self-identified ethnicity n (%) European1153 (91.6%)145 (61.2%)1008 (98.6%) African American69 (5.5%)69 (29.1%)- Native American8 (0.6%)8 (3.4%)-< 0.001 Asian15 (1.2%)4 (1.7%)11 (1.1%) Other14 (1.1%)11 (4.6%)3 (0.03%)Relation to recipient n (%) Living unrelated donor246 (19.5%)56 (23.6%)190 (18.6%) Living related1013 (80.5%)181 (76.4%)832 (81.4%)0.10Relation status n (%) Mother343 (33.9%)18 (9.9%)325 (39.1%) Sibling297 (29.3%)68 (37.6%)229 (27.5%) Father211 (20.8%)15 (8.3%)196 (23.6%)< 0.001 Child73 (7.2%)52 (28.7%)21 (2.5%) Other89 (8.8%)28 (15.5%)61 (7.3%) Table 1Living kidney donor candidate characteristicsDonor candidate characteristicAll (N = 1259)United States (n = 237)International (n = 1022)P-valueAge, median (IQR)47 (38–55)39 (31–49)48 (39–56)< 0.001Sex, female / male n (%)702 (56%)/557 (44%)135 (57%)/102 (43%)567 (55%)/455 (45%)0.73Self-identified ethnicity n (%) European1153 (91.6%)145 (61.2%)1008 (98.6%) African American69 (5.5%)69 (29.1%)- Native American8 (0.6%)8 (3.4%)-< 0.001 Asian15 (1.2%)4 (1.7%)11 (1.1%) Other14 (1.1%)11 (4.6%)3 (0.03%)Relation to recipient n (%) Living unrelated donor246 (19.5%)56 (23.6%)190 (18.6%) Living related1013 (80.5%)181 (76.4%)832 (81.4%)0.10Relation status n (%) Mother343 (33.9%)18 (9.9%)325 (39.1%) Sibling297 (29.3%)68 (37.6%)229 (27.5%) Father211 (20.8%)15 (8.3%)196 (23.6%)< 0.001 Child73 (7.2%)52 (28.7%)21 (2.5%) Other89 (8.8%)28 (15.5%)61 (7.3%) Living kidney donor candidate characteristics Table 2 summarizes the characteristics of kidney transplant recipient candidates. US recipient candidates were significantly older than international candidates (median age, 47 vs. 32 years; P < 0.001). The distribution of underlying diagnoses is also presented in Table 2.Table 2Living donor kidney transplant recipient candidate characteristicsRecipient candidate characteristicAll (N = 1259)United States (n = 237)International (n = 1022)P-valueAge, median (IQR)34 (IQR 25–47)47 (34–59)32 (24–43)< 0.001Female / Male597 (47%)/662 (53%)101 (43%)/136 (57%)496 (49%)/526 (51%)0.12Causes of kidney disease Possible genetic diseasea503 (39.9%)100 (42.6%)403 (38.0%)0.20 Nongenetic diseaseb390 (31%)62 (25.8%)328 (33.2%) Unknown366 (29.1%)75 (31.6%)291 (28.8%)Possible genetic kidney diseases Alport syndrome96 (7.6%)13 (5.5%)83 (8.1%)< 0.001 ADPKD84 (6.7%)25 (10.5%)59 (5.8%) FSGS55 (4.4%)15 (6.3%)40 (3.9%) FMF/Amyloidosis44 (3.5%)-44 (4.3%) Atypical HUS40 (3.2%)2 (0.8%)38 (3.7%) CAKUT30 (2.4%)2 (0.8%)28 (2.7%) C3 Glomerulopathy22 (1.7%)022 (2.1%) Nephronophthisis17 (1.3%)1 (0.4%)16 (1.6%) Unclassified41 (3.3%)9 (3.8%)32 (3.1%) Other74 (5.9%)33 (13.9%)41 (4.0%)ADPKD, autosomal dominant polycystic kidney disease; CAKUT, congenital abnormalities of the kidney and urinary tract; FSGS, focal segmental glomerulosclerosis; FMF, familial Mediterranean fever; HUS, hemolytic uremic syndrome ; IQR, interquartile ranges.aPossible genetic kidney disease was assigned based on clinical features suggestive of inherited disease in the absence of genetic confirmation.bNongenetic disease was assigned when clinical evaluation identified a clear acquired or nonhereditary etiology based on history, comorbidities, laboratory data, imaging, and/or biopsy findings. Table 2Living donor kidney transplant recipient candidate characteristicsRecipient candidate characteristicAll (N = 1259)United States (n = 237)International (n = 1022)P-valueAge, median (IQR)34 (IQR 25–47)47 (34–59)32 (24–43)< 0.001Female / Male597 (47%)/662 (53%)101 (43%)/136 (57%)496 (49%)/526 (51%)0.12Causes of kidney disease Possible genetic diseasea503 (39.9%)100 (42.6%)403 (38.0%)0.20 Nongenetic diseaseb390 (31%)62 (25.8%)328 (33.2%) Unknown366 (29.1%)75 (31.6%)291 (28.8%)Possible genetic kidney diseases Alport syndrome96 (7.6%)13 (5.5%)83 (8.1%)< 0.001 ADPKD84 (6.7%)25 (10.5%)59 (5.8%) FSGS55 (4.4%)15 (6.3%)40 (3.9%) FMF/Amyloidosis44 (3.5%)-44 (4.3%) Atypical HUS40 (3.2%)2 (0.8%)38 (3.7%) CAKUT30 (2.4%)2 (0.8%)28 (2.7%) C3 Glomerulopathy22 (1.7%)022 (2.1%) Nephronophthisis17 (1.3%)1 (0.4%)16 (1.6%) Unclassified41 (3.3%)9 (3.8%)32 (3.1%) Other74 (5.9%)33 (13.9%)41 (4.0%)ADPKD, autosomal dominant polycystic kidney disease; CAKUT, congenital abnormalities of the kidney and urinary tract; FSGS, focal segmental glomerulosclerosis; FMF, familial Mediterranean fever; HUS, hemolytic uremic syndrome ; IQR, interquartile ranges.aPossible genetic kidney disease was assigned based on clinical features suggestive of inherited disease in the absence of genetic confirmation.bNongenetic disease was assigned when clinical evaluation identified a clear acquired or nonhereditary etiology based on history, comorbidities, laboratory data, imaging, and/or biopsy findings. Living donor kidney transplant recipient candidate characteristics ADPKD, autosomal dominant polycystic kidney disease; CAKUT, congenital abnormalities of the kidney and urinary tract; FSGS, focal segmental glomerulosclerosis; FMF, familial Mediterranean fever; HUS, hemolytic uremic syndrome ; IQR, interquartile ranges. Possible genetic kidney disease was assigned based on clinical features suggestive of inherited disease in the absence of genetic confirmation. Nongenetic disease was assigned when clinical evaluation identified a clear acquired or nonhereditary etiology based on history, comorbidities, laboratory data, imaging, and/or biopsy findings. Genetic Testing in Living Donor Transplant Evaluations Genetic testing was performed as part of the assessment process in 23.4% (295/1259) of registry-reported LKD evaluations (Table 3), reflecting practice patterns among participating centers rather than the overall prevalence of genetic testing in all LKD evaluations. In 63.7% (188/295) of these LKD evaluations that included genetic testing, genetic testing was first conducted in the recipient candidate, whereas in 36.3% (107/295) of these LKD evaluations, genetic testing was performed only in the LKD candidate without previous recipient candidate testing. There were striking geographic differences in the use of genetic testing. Donor-recipient pairs evaluated at US transplant centers had substantially higher odds of undergoing any genetic testing compared with those evaluated at non-US centers (OR: 9.95, 95% CI: 7.17–13.82, P < 0.001). When stratified by geographic origin, US LKD candidates underwent genetic testing were significantly younger than international LKD candidates (median age 37 vs. 49 years, P < 0.001), and their intended recipients were older (46 vs. 31 years, P < 0.001). Most donors undergoing genetic testing were related to the transplant recipient (88.1%, 260/295), though unrelated LKD candidates were more common overall in the US cohort (19.9% [31/156] vs. 2.9% [4/139], P < 0.001; Table 3).Table 3Characteristics of living donor evaluations with genetic testingCharacteristicAll (N = 295)United States (n = 156)International (n = 139)P-valueDonor age median (IQR)42 (34–54)37 (29–46)49 (39–56.5)< 0.001Recipient age median (IQR)38 (25–52)46 (34–61)31 (20.5–41)< 0.001Donor sex, F/M n (%)168 (57%)/127 (43%)89 (57%)/67 (43%)79 (57%)/60 (43%)0.99Recipient sex, F/M n (%)112 (38%)/183 (62%)60 (38%)/96 (62%)52 (37%)/87 (63%)0.90Relation to recipient candidate Living related260 (88.1%)125 (80.1%)135 (97.1%) Living unrelated donor35 (11.9%)31 (19.9%)4 (2.9%)< 0.001IQR, interquartile range. Table 3Characteristics of living donor evaluations with genetic testingCharacteristicAll (N = 295)United States (n = 156)International (n = 139)P-valueDonor age median (IQR)42 (34–54)37 (29–46)49 (39–56.5)< 0.001Recipient age median (IQR)38 (25–52)46 (34–61)31 (20.5–41)< 0.001Donor sex, F/M n (%)168 (57%)/127 (43%)89 (57%)/67 (43%)79 (57%)/60 (43%)0.99Recipient sex, F/M n (%)112 (38%)/183 (62%)60 (38%)/96 (62%)52 (37%)/87 (63%)0.90Relation to recipient candidate Living related260 (88.1%)125 (80.1%)135 (97.1%) Living unrelated donor35 (11.9%)31 (19.9%)4 (2.9%)< 0.001IQR, interquartile range. Characteristics of living donor evaluations with genetic testing IQR, interquartile range. Genetic testing strategies differed by region as follows: international centers primarily used a recipient-first approach (128/139, 92.1%), whereas US centers more often tested the donor directly (96/156, 61.5%; P < 0.001; Table 4).Table 4Genetic testing approaches in living donor kidney transplant evaluationsGenetic testing approachAllUnited StatesInternationalP-valueRecipient candidate firstN = 188n = 60n = 128Testing method Single or limited gene panel48 (25.6%)5 (8.3%)43 (35.2%) Comprehensive gene panel104 (55.3%)50 (83.3%)54 (40.6%)< 0.001 WES34 (18.1%)3 (5.0%)31 (24.2%) APOL1 RRV testing1 (0.5%)1 (1.7%)- Chromosomal microarray11 (1.7)-Recipient candidate counseling156 (83.0%)45 (75%)111 (86.7%)0.09LKD candidate testing after recipient testingN = 132n = 40n = 92LKD positive test after recipient testing42 (32%)9 (22.5%)33 (35.9%)0.13LKD candidate counseling98 (74.2%)36 (90%)62 (67.4%)0.01Direct LKD candidate testingN = 107n = 96n = 11 APOL1 RRV testing43 (40.2%)43 (44.8%)-< 0.001 Single or limited gene panel14 (13.1%)8 (8.3%)6 (54.5%) Comprehensive gene panel41 (38.3%)37 (38.5%)4 (36.3%) WES9 (8.4%)8 (8.3%)1 (9.1%)LKD candidate positive test11 (10.3%)9 (9.4%)2 (18%)0.32LKD candidate counseling86 (80.4%)75 (78.1%)11 (100%)0.40APOL1 RRV, apolipoprotein L-1 renal risk variant; LKD, living kidney donor; RRV, renal risk variant; WES, whole exome sequencing. Table 4Genetic testing approaches in living donor kidney transplant evaluationsGenetic testing approachAllUnited StatesInternationalP-valueRecipient candidate firstN = 188n = 60n = 128Testing method Single or limited gene panel48 (25.6%)5 (8.3%)43 (35.2%) Comprehensive gene panel104 (55.3%)50 (83.3%)54 (40.6%)< 0.001 WES34 (18.1%)3 (5.0%)31 (24.2%) APOL1 RRV testing1 (0.5%)1 (1.7%)- Chromosomal microarray11 (1.7)-Recipient candidate counseling156 (83.0%)45 (75%)111 (86.7%)0.09LKD candidate testing after recipient testingN = 132n = 40n = 92LKD positive test after recipient testing42 (32%)9 (22.5%)33 (35.9%)0.13LKD candidate counseling98 (74.2%)36 (90%)62 (67.4%)0.01Direct LKD candidate testingN = 107n = 96n = 11 APOL1 RRV testing43 (40.2%)43 (44.8%)-< 0.001 Single or limited gene panel14 (13.1%)8 (8.3%)6 (54.5%) Comprehensive gene panel41 (38.3%)37 (38.5%)4 (36.3%) WES9 (8.4%)8 (8.3%)1 (9.1%)LKD candidate positive test11 (10.3%)9 (9.4%)2 (18%)0.32LKD candidate counseling86 (80.4%)75 (78.1%)11 (100%)0.40APOL1 RRV, apolipoprotein L-1 renal risk variant; LKD, living kidney donor; RRV, renal risk variant; WES, whole exome sequencing. Genetic testing approaches in living donor kidney transplant evaluations APOL1 RRV, apolipoprotein L-1 renal risk variant; LKD, living kidney donor; RRV, renal risk variant; WES, whole exome sequencing. Testing Transplant Candidate First Approach: Donor Candidate Results Table 4 summarizes the genetic testing approaches used in LKD evaluations. Of the 188 intended recipients who underwent genetic testing, 132 (70.2%) prompted genetic testing of their potential donors. Among these LKD candidates, the types of genetic tests performed included comprehensive kidney disease gene panel (25.0%, 33/132), cascade genetic testing (27.3%, 36/132), single gene/limited gene panel (36.4%, 48/132), whole exome sequencing (5.3%, 7/132), and chromosomal microarray (0.8%, 1/132). APOL1 RRV testing alone was performed in 5.3% (7/132) LKD candidates, whose corresponding recipient candidates had previously undergone genetic evaluation using the comprehensive kidney gene panel. 74.2% (98/132) of the LKD candidates received formal genetic counseling. Among the 132 LKD candidates tested after recipient genetic evaluation, 31.8% (42/132) were reported as positive genetic test results. These results were classified as follows: pathogenic or likely pathogenic variants (95.2%, 40/42) and APOL1 high-risk genotype (4.8%, 2/42; Figure 2). The most common variants were familial Mediterranean fever gene (31.0%, 13/42) and collagen type IV alpha 3 gene (26.2%, 11/42).Figure 2Genetic findings in sequentially tested living kidney donor candidates following recipient genetic evaluation. Distribution of genes associated with pathogenic, likely pathogenic and APOL1 (apolipoprotein L1) high-risk genotype variants identified in donor candidate testing following recipient candidate genetic evaluation. The figure depicts the number of variants identified per gene. The zygosity of each variant is indicated. Among the 132 sequential LKD candidates tested, 42 (31.8%) were reported as positive genetic test results. These results were classified as follows: pathogenic or likely pathogenic variants (n = 40, 95.2%) and APOL1 high-risk genotype (n = 2, 4.8%). CFI (complement factor I), COL4A3 (collagen type IV alpha 3 chain), COL4A4 (collagen type IV alpha 4 chain), COL4A5 (collagen type IV alpha 5 chain), COQ8B (coenzyme Q8B, also known as ADCK4), INF2 (inverted Formin 2), MEFV (Mediterranean fever gene), and PKD1 (Polycystin 1). LKD, living kidney donor. Genetic findings in sequentially tested living kidney donor candidates following recipient genetic evaluation. Distribution of genes associated with pathogenic, likely pathogenic and APOL1 (apolipoprotein L1) high-risk genotype variants identified in donor candidate testing following recipient candidate genetic evaluation. The figure depicts the number of variants identified per gene. The zygosity of each variant is indicated. Among the 132 sequential LKD candidates tested, 42 (31.8%) were reported as positive genetic test results. These results were classified as follows: pathogenic or likely pathogenic variants (n = 40, 95.2%) and APOL1 high-risk genotype (n = 2, 4.8%). CFI (complement factor I), COL4A3 (collagen type IV alpha 3 chain), COL4A4 (collagen type IV alpha 4 chain), COL4A5 (collagen type IV alpha 5 chain), COQ8B (coenzyme Q8B, also known as ADCK4), INF2 (inverted Formin 2), MEFV (Mediterranean fever gene), and PKD1 (Polycystin 1). LKD, living kidney donor. Direct Donor Candidate Genetic Testing Approach Direct genetic testing of the LKD candidates was performed in 8.5 (107/1259) of LKD candidate evaluations, of whom 80.4% (86/107) received formal genetic counseling (Table 4). Self-identified Ethnicity Based APOL1 Genetic Testing of the Donor Candidate Among the 107 LKD candidates, 43 LKD candidates (40.2%) underwent APOL1 RRV testing alone; all testing was performed at US transplant centers. Of these 43 candidates, 29 candidates had biologically related intended recipients, most of whom had chronic kidney disease of unknown etiology (n = 25). An APOL1 high-risk genotype (2 RRVs) was identified in 5 of the 43 tested candidates (11.6%; Figure 3).Figure 3Genetic testing results among living kidney donor candidates undergoing direct testing by different testing methods. An APOL1 (apolipoprotein L1) high-risk genotype (2 renal risk variants) was identified in 5 of the 43 LKD candidates tested for APOL1 (11.6%). Among the 64 candidates who underwent monogenic kidney disease testing by different methods, 6 (9.4%) had positive genetic test results, including pathogenic or likely pathogenic variants (n = 5, 83.3%) and an APOL1 high-risk genotype (n = 1, 16.7%). COL4A3 (collagen type IV alpha 3 chain), HBB (hemoglobin subunit beta, MEFV (familial Mediterranean fever gene), SERPINA1 (Serpin Family A Member 1) and VHL (Von Hippel–Lindau tumor suppressor). LKD, Living kidney donor. Genetic testing results among living kidney donor candidates undergoing direct testing by different testing methods. An APOL1 (apolipoprotein L1) high-risk genotype (2 renal risk variants) was identified in 5 of the 43 LKD candidates tested for APOL1 (11.6%). Among the 64 candidates who underwent monogenic kidney disease testing by different methods, 6 (9.4%) had positive genetic test results, including pathogenic or likely pathogenic variants (n = 5, 83.3%) and an APOL1 high-risk genotype (n = 1, 16.7%). COL4A3 (collagen type IV alpha 3 chain), HBB (hemoglobin subunit beta, MEFV (familial Mediterranean fever gene), SERPINA1 (Serpin Family A Member 1) and VHL (Von Hippel–Lindau tumor suppressor). LKD, Living kidney donor. Direct Donor Candidate Genetic Testing for Monogenic Kidney Diseases Testing for monogenic kidney diseases was performed in 64 LKD candidates (53 from US centers and 11 from international centers); 67.2% of these candidates (43/64) were biologically related to their intended recipients. Comprehensive kidney disease gene panels were used in 41 LKD candidates including 16 with related recipient candidates with a known or suspected genetic kidney disease. Single-gene or limited panels were performed in 14 candidates, 8 of whom had related recipient candidates with possibly genetic condition. Whole exome sequencing was performed in 9 candidates with 6 having related recipient candidates with known or suspected genetic kidney disease (Table 4). Among these 64 LKD candidates who underwent direct genetic testing for monogenic kidney diseases, 9.4% (6/64) had positive genetic test results. These results were classified as follows: pathogenic or likely pathogenic variants (83.3%, 5/6) and APOL1 high-risk genotype (16.7%, 1/6; Figure 3). Outcomes of LKD Candidate Evaluations Of the 1259 LKD candidate evaluations, 1053 (83.6%) resulted in successful living kidney donation. An additional 72 LKD candidates (5.7%) were approved for donation but had not yet donated at the time of data entry. Fifty-six LKD candidates (4.4%) were still undergoing evaluation, 67 (5.3%) were not accepted as donors, and the outcome was unknown for 11 evaluations (0.9%). Outcomes of Living Donor Candidate Evaluations Following Genetic Testing Genetic testing was included in the assessment process for 295 LKD evaluations; of these, 64.7% (191/295) were accepted for donation and 47.5% (140/295) successfully donated during the study timeframe. Thirty-four LKD candidates (11.5%) were still undergoing evaluation, and the outcome was recorded as unknown for 9 LKD evaluations (3.0%). Among LKD evaluations where genetic testing was performed, 20.7% candidates (61/295) were not accepted for donation, and 7.8% (23/295) of these were attributed to the genetic test results. Remarkably, 6 of these denials occurred despite negative or nonactionable genetic findings, including 1 candidate who was a carrier for the SERPINA1 which encodes Alpha-1 antitrypsin and 5 candidates with benign variants in complement genes (complement factor H, n = 3; complement component 3, n = 1; complement factor H related 3, n = 1). Additional reasons for nonacceptance are shown in Figure 4.Figure 4Reasons for nonapproval among living kidney donor candidates who underwent genetic testing, stratified by region. Among the 61 donor candidates who were not approved for donation, genetic test results were the primary reason for denial in 23 cases (37.7%). Reasons for nonapproval among living kidney donor candidates who underwent genetic testing, stratified by region. Among the 61 donor candidates who were not approved for donation, genetic test results were the primary reason for denial in 23 cases (37.7%). In univariate logistic regression analysis restricted to LKD evaluations that included genetic testing, 2 variables were significantly associated with nonacceptance. Older LKD candidate age at assessment was associated with lower odds of nonacceptance (OR: 0.96; 95% CI: 0.94–0.98; P = 0.001), whereas undergoing LKD candidate genetic testing was associated with higher odds of nonacceptance (OR: 3.64; 95% CI: 1.38–12.60; P = 0.02). Other variables including LKD candidate sex, recipient age and sex, evaluation at a US versus international center, ethnicity, degree of donor-recipient relationship, recipient kidney disease etiology, genetic testing methods and results were not significantly associated with nonacceptance in univariate analyses. In multivariable logistic regression analysis restricted to LKD evaluations that included genetic testing, LKD candidate age remained independently associated with lower odds of nonacceptance (adjusted OR: 0.89; 95% CI: 0.83–0.95; P < 0.001). Additional analyses demonstrated that the association between younger LKD candidate age and nonacceptance persisted after accounting for genetic test results, donor-recipient relationship, APOL1 testing, and US versus international center, with no significant interactions observed. Multicollinearity was assessed using variance inflation factors, with no evidence of problematic collinearity identified. Discussion Findings from LDGen registry demonstrate substantial geographic heterogeneity in the utilization and approach to genetic testing among LKD candidate evaluations across transplant centers. US centers favored direct LKD candidate testing, even after excluding ethnicity-based APOL1 RRV screening whereas international centers predominantly adopted a transplant candidate-first approach, relying on targeted panels or whole exome sequencing to make a diagnosis in the transplant candidate. Demographic and clinical differences were observed across regions, with US recipient candidates generally older and having differing distributions of genetic kidney diseases. These variations may reflect differences in referral patterns, clinical practices, disease prevalence and country-specific economic or reimbursement factors influencing access to genetic testing. Despite inclusion criteria identifying candidates in whom genetic testing could be clinically informative, only a minority (23.4%) ultimately underwent testing in this targeted cohort, reflecting real-world, nonprotocolized practice patterns. This variability is likely multifactorial, driven by clinician-level barriers such as limited training and confidence in genetic testing, restricted access to genetic counseling, and under-recognition of indications despite growing evidence of utility.9,18, 19, 20 Institutional factors including the absence of multidisciplinary genetics teams, standardized workflows, and integrated bioinformatics support further limit adoption, even though specialized clinics demonstrate high diagnostic yields.21, 22, 23, 24, 25, 26 Economic and reimbursement disparities between countries may play a role.27, 28, 29, 30 In addition, recipient-first testing strategies, although clinically appropriate, may reduce observed donor testing rates, as donor evaluation is often deferred unless a pathogenic variant is identified in the recipient.9,23,29 Patient-level considerations, including concerns about genetic discrimination and family implications, also influence uptake.9,31 The marked geographic variation observed likely reflects these combined factors, as well as broader inequities in genomic representation and access to expertise, which can limit confidence in variant interpretation in diverse populations.30,32 However, these observations should also be interpreted in light of study design limitations, including the cross-sectional nature of the data and the use of a highly selected sample, which may limit generalizability. Collectively, these findings highlight the need for coordinated efforts to address clinician education, infrastructure, reimbursement, and global equity to support broader and more consistent implementation of genetic testing in transplant evaluation. This divergence in genetic testing practices raises important clinical considerations. Kidney Disease: Improving Global Outcomes 2017 guideline recommends a comprehensive, phenotype-informed assessment of the recipient candidate, particularly when genetic kidney disease is suspected.33 Expert opinion-based guidance from the American Society of Transplantation’s Living Donor Community of Practice recommends the following recipient candidate-first strategy: determining the genetic basis of disease in an affected family member, often the recipient candidate, followed by targeted testing (cascade testing) in the asymptomatic LKD candidate.9 Operationally, this involves establishing a clinical diagnosis in the affected individual, conducting phenotype-relevant panel testing, and then testing at-risk relatives only if a potential causal variant is identified. Although this approach is common in international centers, our data indicate that it is less frequently implemented in the US. Instead, US centers, at least at the time of the collection of this data, more often pursue direct genetic testing of LKD candidates, even after excluding the ethnicity based APOL1 RRV screening, including in LKD candidates whose related recipient candidate has a confirmed or suspected genetic kidney disorder. Despite its increasing use, direct LKD candidate testing outside of APOL1 alone presents several challenges. In asymptomatic healthy individuals, interpreting VUS or even predicted pathogenic variants can be problematic, particularly in populations lacking robust genomic databases. This is especially true for minority populations, where variant allele frequencies may be underrepresented, increasing the risk of misclassification.34, 35, 36 An important aspect of this study is the impact of genetic testing on the outcomes of LKD candidate evaluations. Genetic test results play a critical role in LKD eligibility determinations, underscoring the importance of transparent evaluation criteria and informed decision-making. Our findings show that genetic findings contributed to nonacceptance in 7.8% of all evaluated candidates who underwent genetic testing (23/295). Particularly, among candidates who were declined after testing, genetic findings accounted for a substantial proportion of decisions; however, this included cases in which declines occurred despite negative or nonactionable results, as well as instances where VUS influenced clinical decision-making. Over-interpretation of VUS may contribute to overly conservative decision-making and the potential for “defensive medicine,” particularly in the absence of clear, evidence-based guidance. These challenges are further amplified when LKD candidates undergo direct genetic testing without adequate consideration of family history or, when family history is present, without careful evaluation of the affected individual’s phenotype and likely underlying diagnosis. These may be particularly problematic in individuals from underrepresented populations as they have limited representation in genomic reference databases, resulting in higher rates of VUS and greater uncertainty in interpretation. This may increase the risk of inappropriate donor exclusion in these populations. Together, these findings underscore the urgent need for standardized, evidence-based frameworks to guide the integration of genetic data into donor evaluation. Given the complexity of interpreting genetic data, especially in asymptomatic individuals, it is essential that potential donors and recipients receive thorough pretest counseling to ensure informed consent, followed by post-test counseling to interpret results and understand their implications.9,14 Genetic counseling was provided to 74% of LKD candidates, with higher rates in the US compared with international centers (90% vs. 67%), highlighting important system-level differences in access to specialized genetics services. These differences may reflect variation in infrastructure, regulatory frameworks, and reimbursement policies, which influence the integration of genetic counseling into transplant evaluation workflows. Additionally, the registry does not distinguish between pretest and post-test counseling, an important consideration for interpreting the clinical impact and consistency of counseling practices across centers. In this study, younger donor age was associated with a higher likelihood of nonacceptance, independent of genetic findings. This may reflect more conservative selection because of longer projected lifetime risk, increased scrutiny in the context of uncertain or incidental findings, or center-level risk thresholds aimed at minimizing long-term donor harm. However, this finding should be interpreted cautiously given the registry-based design and warrants validation in larger, population-based cohorts. Implementing genetic testing at scale in kidney transplant evaluation is increasingly feasible but requires coordinated attention to cost-effectiveness, infrastructure, workforce, and equity. Declining sequencing costs and early testing strategies improve efficiency, with reported cost reductions of up to 41% through avoidance of unnecessary procedures and more targeted care.18,27 A recipient-first cascade approach optimizes diagnostic yield (21%–47%) and enables cost-effective, targeted donor testing, while selective testing of high-risk donors is more practical than universal screening.20,22,37,38 However, successful implementation depends on robust laboratory and bioinformatics infrastructure, multidisciplinary variant interpretation, and integration into clinical workflows.25,27 Workforce limitations, particularly shortages of genetic counselors and trained clinicians, remain a key barrier, contributing to underutilization despite clear clinical utility.18,25,39 These challenges are amplified in middle-income healthcare settings, where limited reimbursement, infrastructure, and genomic representation constrain adoption and may impact variant interpretation accuracy.38,39 Overall, although genetic testing demonstrably alters clinical management, scalable and equitable implementation will require standardized frameworks, investment in workforce and infrastructure, and policies supporting broader access across diverse healthcare settings.37,40 This study has several considerations. First, the LDGen registry is not a population-based dataset of consecutive donor evaluations; rather, enrollment was based on predefined inclusion criteria, resulting in a cohort enriched for cases in which genetic evaluation was considered or performed. As such, the dataset may not be fully representative of all LKD evaluations, and the denominator of total evaluations is not captured. This limits interpretation of reported genetic testing rates and constrains comparisons across geographic regions and centers. Second, participation was limited to a subset of countries and transplant centers, which may not fully reflect global LKD transplant practices. In addition, variability in practice patterns across regions, along with the inherent limitations of a registry-based, cross-sectional design, may affect generalizability and preclude causal inference. Third, the use of deidentified registry data may introduce inaccuracies related to incomplete or inconsistent data entry. Fourth, selection bias is possible, as the registry may preferentially include evaluations that advanced further in the transplant process or were deemed appropriate for genetic assessment. Finally, although center-level clustering may influence observed patterns, hierarchical modeling was not feasible because of the structure of the registry and limited sample sizes within individual centers. These considerations highlight the inherent challenges of real-world, multicenter registry studies and underscore the need for standardized testing protocols, uniform interpretation frameworks, and consensus guidelines to guide genetic evaluation in LKD transplantation. At the same time, this study has notable strengths. It represents 1 of the largest multicenter analyses of genetic testing in LKD transplantation to date, including 1259 LKD evaluations from 24 transplant centers across 10 countries. Importantly, this is not a population-based cohort of all donor evaluations, but rather a targeted registry enriched for cases in which genetic evaluation was considered or performed. Within this context, genetic testing was performed in 295 evaluations (23%), reflecting practice patterns among participating centers rather than overall testing prevalence. Despite this enrichment, the breadth of participating centers and the inclusion of both US and international experiences provide valuable insight into contemporary practice and highlight the need to establish the place of genetic testing in LKD evaluation to allow for standardized testing protocols, uniform interpretation frameworks, and consensus guidelines to inform genetic evaluation in LKD transplantation. In conclusion, LDGen registry provides the first international snapshot of genetic testing practices in LKD transplantation, highlighting critical demographic, geographic, and procedural differences. Our findings underscore that while genetic testing is being integrated into LKD evaluations, its application and role in LKD acceptance has not been established, and its practice varies across regions. Despite the clinical rationale for cascade testing, its implementation remains uneven, particularly in the US, where direct donor candidate testing was frequently performed even in families with potential genetic diagnosis. Genetic test results influenced donor eligibility decisions even when test results were equivocal or negative, emphasizing the risk of testing without access to genetics expertise. Younger donor age was independently associated with nonacceptance, though positive genetic findings did not uniformly result in declinations. Together, these results highlight the substantial clinical implications of genetic testing in LKD transplant and support the development of harmonized, evidence-based guidelines. Incorporating pre- and post-test genetic counseling, phenotype-driven testing strategies, and population-specific data will be essential to optimize donor safety and transplant outcomes. LDGen’s initial data lays the groundwork for future efforts to refine best practices, reduce variability, and promote responsible and equitable integration of genetic information into transplantation care. Disclosure YC receives funding related to APOL1 from the Mid-America Transplant Foundation (NCT05656261) and funding related to genetic kidney disease from the Polycystic Kidney Disease Foundation (Center of Excellence Director) and Saint Louis University (IM seed fund). KLL is supported by the Mid-America Transplant/Jane A. Beckman Endowed Chair in Transplantation, and receives funding related to APOL1 from the Mid-America Transplant Foundation (NCT05656261) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK R01DK120551). RBM receives honoraria from Alexion, CSL Behring, Biogen/Hibio, Eledon, Hansa, Sanofi, and VERICI Dx. She is a deputy editor of the American Journal of Transplantation, a member of the Board of the Trustees of the Banff Foundation for Allograft Pathology. YC receives consultancy from Vera Therapeutics and Vertex Pharmaceuticals and is Scientific Advisor at Nephronomics. KLL receives consultancy from CareDx and Maze Therapeutics, and speaker honoraria from Sanofi. AV receives speaker honoraria from Alexion. The other authors declared no competing interests.